Drug Profile
Research programme: hepatitis B virus therapeutics - AiCuris
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer AiCuris
- Class Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Hepatitis-B in Germany
- 25 Jan 2016 Early research in Hepatitis B in Germany (unspecified route) (AiCuris pipeline; January 2016)